Top 14+ Cc-5013-nhl-008 hay nhất
-
1.Lenalidomide Plus Rituximab Followed By ...
Recent studies in frontline and relapsed/refractory NHL show high activity for ... Other Name: CC-5013, Revlimid ... Other Study ID Numbers: CC-5013-NHL-008.
Xem chi tiết » -
2.Rituximab Plus Lenalidomide For Patients With Relapsed ...
This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab ...
Xem chi tiết » -
3.Lenalidomide Lymphoma MAGNIFY (CC-5013-NHL-008)
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab ...
Xem chi tiết » -
4.Cc-5013-nhl-008 Magnify - Michigan Cancer Research Consortium
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab ...
Xem chi tiết » -
5.A Phase 3B Randomized Study Of Lenalidomide (CC-5013) Plus ...
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide ... CC5013NHL008, Celgene Corporation.
Xem chi tiết » -
6.Cc-5013-nhl-008 (magnify) - StiL
CC-5013-NHL-008, 2017-002290-19, NCT01996865. Eine randomisierte Phase 3b Studie zur Erhaltungstherapie durch Kombination von Lenalidomid (CC-5013) und ...
Xem chi tiết » -
7.MAGNIFY: A Randomized, Phase 3b Trial In Patients With Relapsed ...
20 May 2015 · ... of the immunomodulatory agent lenalidomide (Revlimid) with rituximab (R2) is a promising therapeutic option for patients with R/R NHL.
Xem chi tiết » -
8.Search For 2017-002290-19 - Clinical Trials Register
EudraCT Number: 2017-002290-19, Sponsor Protocol Number: CC-5013-NHL-008 ... Full Title: A Phase 3b randomized study of lenalidomide (CC-5013) plus ...
Xem chi tiết » -
9.Immunomodulatory Drugs Revlimid (lenalidomide) And CC-4047 ...
Revlimid (Lenalidomide, CC-5013) and CC-4047 are IMiDs immunomodulatory drugs that have been ... 2008 Dec;57(12):1849-59. doi: 10.1007/s00262-008-0512-7.
Xem chi tiết » -
10.A Phase III Study Of Lenalidomide Plus Rituximab Versus Placebo ...
10 May 2019 · Lenalidomide improved efficacy of rituximab in patients with recurrent indolent lymphoma, with an acceptable safety profile. Missing: 008 | Must include: 008
Xem chi tiết » -
11.[PDF] Lenalidomide-accord-epar-product-information_en.pdf
MAGNIFY - CC-5013-NHL-008. A total of 232 subjects who were at least 18 years of age with histologically confirmed FL (Grade 1, 2,.
Xem chi tiết » -
12.[PDF] Revlimid, INN-lenalidomide - European Medicines Agency
14 Nov 2019 · MAGNIFY (Study CC-5013-NHL-008). This is a multicenter, 2-part Phase 3b study with an open-label, single-arm Initial Treatment Period with.
Xem chi tiết » -
13.Revlimid 2.5 Mg Hard Capsules - Print Friendly - (emc)
Revlimid 2.5 mg Hard Capsules - Summary of Product Characteristics (SmPC) by ... Additionally, adverse drug reactions from supportive study NHL-008 have ...
Xem chi tiết » -
14.Revlimid 5 Mg Hard Capsules - Summary Of Product Characteristics ...
Exact confidence interval for binomial distribution. Follicular lymphoma for patients refractory to Rituximab. MAGNIFY - CC-5013-NHL-008. A total of 232 ...
Xem chi tiết »